Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
namilumab
- Development stage
- Phase 2
- Lead developer
- Kinevant Sciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
Namilumab is a fully human monoclonal antibody (IgG1 kappa) that targets and neutralizes granulocyte macrophage-colony stimulating factor (GM-CSF, also known as colony stimulating factor 2 or CSF2). By inhibiting GM-CSF, namilumab reduces the recruitment and activation of macrophages and monocytes, which are implicated in inflammatory and autoimmune diseases. It has been investigated for use in rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and pulmonary sarcoidosis. Namilumab is administered as a once-monthly subcutaneous injection. The drug was originally produced by Micromet Inc., with subsequent development by Takeda Pharmaceuticals International, Izana Bioscience, Kinevant Sciences, and Amgen[1][3][6][7].
- Other names
- namilumab
02
Targets
GM-CSF (Granulocyte-macrophage colony-stimulating factor)
Beyond the preview
Go deeper on namilumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on namilumab.